Company Overview of Famy Care Ltd.
Famy Care Ltd. manufactures and supplies female contraceptive pills, injectables, and devices. It offers oral and emergency contraceptives, intra uterine devices, tubal ligation rings, progestagen only pills, hormonal tablets, and cancer detection kits. Famy Care Ltd. was founded in 1987 and is based in Mumbai, India.
12/14, Veer Nariman Road
Founded in 1987
Key Executives for Famy Care Ltd.
Famy Care Ltd. does not have any Key Executives recorded.
Famy Care Ltd. Key Developments
TA Associates Reportedly In Talks To Acquire Famy Care's Stake
Oct 8 14
TA Associates Management, L.P. is in advanced talks to acquire a 35% stake in Famy Care Ltd. from AIF Capital Limited and Famy Care Ltd.'s promoters for $200 million, The Economic Times reported citing three people involved in the deal. The deal is expected to be signed post Diwali. Credit Suisse AG has been tapped by TA Associates Management, L.P. Naveen Wadhera, Asia Co-Head of TA Associates Management, L.P. did not respond to emailed queries.
Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation
Apr 15 14
Actavis plc announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(R) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(R) FE under its pending Abbreviated New Drug Application (ANDA) beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd. in connection with Lupin's pending ANDA for a generic version of Generess(R).
Warner Chilcott plc Enters into Settlement and License Agreement with Mylan Inc. and Mylan Pharmaceuticals Inc. and Famy Care Ltd
Jul 29 13
Warner Chilcott plc has entered into a settlement and license agreement with Mylan Inc. and Mylan Pharmaceuticals Inc. (together, Mylan') and Famy Care Ltd. (Famy Care") to resolve patent litigation related to the company's U.S. Patent No. 5,552,394 (the '394 Patent"), which covers LOESTRIN 24 FE and expires July 22, 2014. Pursuant to the agreement, Mylan and Famy Care have agreed, among other things, not to commence marketing their generic equivalent LOESTRIN 24 FE product until the earlier of July 1, 2014 or the date on which a third party (other than pursuant to the company's January 2009 settlement and license agreement) enters the market with a generic version of LOESTRIN 24 FE in the United States with or without authorization from the company. Pursuant to the agreement, the company's pending '394 Patent litigation with Mylan and Famy Care will be dismissed. The agreement is required to be submitted to, and is subject to the review of, the U.S. Department of Justice and the Federal Trade Commission. The Company had previously received a Paragraph IV certification notice letter from Mylan, as U.S. agent for Famy Care, indicating that Famy Care had submitted to the U.S. Food and Drug Administration an Abbreviated New Drug Application seeking approval to manufacture and sell a generic version of LOESTRIN 24 FE. The company subsequently filed a lawsuit against Famy Care and Mylan in the U.S. District Court for the District of New Jersey charging each with infringement of the '394 Patent.
Similar Private Companies By Industry
Recent Private Companies Transactions